tbuckley/cabot-search huggingface dataset:
ACUTE AND CHRONIC INFLUENZA.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Diphtheria Immunization; Propaganda and Counter-Propaganda.
Journal: JAMA (1933)

Dr. Wilson has faithfully recorded, by reprinting all documents concerned, his controversy with the "antis" over diphtheria immunization. His technic is not that of his opponents, who reprint from medical literature only what serves the ends of their propaganda. His book proves that the antivaccinationists, the antivivisectionists and their like, wherever they may be found, are like "the Colonel's lady and Judy O'Grady, sisters under their skins." British or American, they go to the ends of the earth to find the few regrettable accidents that have occurred in connection with immunization and gloat over them. They display the same cynical disregard for accuracy in England as in the United States, even while using facts to malign truth. Dr. Wilson was attacked, and was compelled to defend himself, which he did with shrewdness, wit and a great deal more good humor than his adversaries, even after his personal motives had been
British Journal of Industrial Medicine, London
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cryptic HBV viremia in anti-HBC positive/HBsAg negative patients with HIV infection is frequently revealed by applying an ultrasensitive droplet digital PCR assay
Authors: Romina Salpini, Vincenzo Malagnino, Mohammad Alkhatib, Lorenzo Piermatteo, Rossana Scutari, Riccardo Chirichiello, Tizana Mulas, Ada Bertoli, Katia Yu La Rosa, Marta Brugneti, Marco Ciotti, Massimo Andreoni, Carlo Federico Perno, Francesca Ceccherini Silberstein, Loredana Sarmati, Valentina Svicher
Journal: Journal of Hepatology (2020)
Paul Gottlieb Werlhof (1699-1767). Thrombocytopenic purpura
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2190: Repurposing the FDA-approved antiviral drug ribavirin as targeted therapy for nasopharyngeal carcinoma
Authors: Andy S. Ding, Joshua Casaos, Sakibul Huq, Henry Brem, Nicolas Skuli, Betty Tyler
Journal: Cancer Research (2019)

Abstract Purpose: Nasopharyngeal carcinoma (NPC) is a squamous cell carcinoma that is often diagnosed at an advanced stage, leading to poor disease-free and overall survival. Accumulating literature suggests that elevated protein expression of EZH2, eIF4E, and IMPDH correlates with poor prognosis in NPC. These three proteins are modulated by the FDA-approved antiviral drug ribavirin, which has recently been repurposed by our laboratory and others as a promising anti-cancer agent. Based on this intersection of molecular signature and drug targets, we investigated the potential use of ribavirin as a therapeutic agent for NPC. Experimental Design: We assessed anti-neoplastic efficacy of ribavirin on human NPC cell lines in vitro using cellular growth assays, flow cytometry, and scratch wound assays. Mechanistic pathways involved were investigated using genomic expression datasets, western blots, and enzymatic activity assays. The effects of combining ribavirin with radiation were assessed via clonogenic assays and flow cytometry. Finally, we evaluated the effects of ribavirin on tumor growth in vivo using human cell line-derived xenograft models. Results: Ribavirin significantly decreased NPC cellular proliferation and migratory capacity in addition to promoting cell cycle arrest and cell death. Modulation of the EZH2, Snail, eIF4E, and IMPDH pathways was observed in response to ribavirin treatment. Ribavirin significantly enhanced the cytotoxic effects of radiation therapy in NPC. Most importantly, ribavirin significantly reduced flank tumor growth in NPC xenograft models. Conclusions: Our work suggests that ribavirin has potent anti-cancer effects in NPC and could represent a safe and promising addition to current NPC treatment regimens. Citation Format: Andy S. Ding, Joshua Casaos, Sakibul Huq, Henry Brem, Nicolas Skuli, Betty Tyler. Repurposing the FDA-approved antiviral drug ribavirin as targeted therapy for nasopharyngeal carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2190.
Depression of drug-metabolizing activity in the human liver by interferon-β
Authors: H Okuno
Journal: Hepatology (1993)

The depressant effect of interferon beta on drugmetabolizing activity in the human liver was investigated. Seven patients with chronic hepatitis C were treated with interferon beta at doses of 3 × 106 to 9 × 106 IU/day for 8 wk. The activities of 7-methoxycoumarin O-demethylase and 7-ethoxycoumarin O-deethylase in specimens obtained by liver biopsy were examined before and after interferon treatment. Theophylline pharmacokinetics were also examined before and after interferon treatment. Interferon beta treatment reduced the activities of both O-dealkylases from 6.0 (100%) to 3.2 (53%) nmol/gm liver per minute and from 1.9 (100%) to 1.1 (58%) nmol/gm liver per minute, respectively (p < 0.05). The total body clearance of theophylline was also decreased (from 0.76 to 0.56 ml/kg/min; p < 0.05), and its elimination half-life was increased (from 8.4 to 11.7 hr; p < 0.05); however, the volume of distribution was not significantly affected. The magnitude of the decreases in enzyme activities and in theophylline clearance varied widely in individual patients and did not correlate with the dose of interferon administered. This study provides the first direct evidence that interferon beta can depress the activity of drugmetabolizing enzymes in the human liver. (HEPATOLOGY 1993;17:65–69.)
PROSTAGLANDINS
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Familial Fatal Varicella
Authors: Ernest B. Hook
Journal: JAMA (1969)

<h3>To the Editor:—</h3> The episode occurred in April 1964, as indicated in the article (Fig 1) on page 306. Thus, the therapy of the family physician must have been "in spite of" the citations by Dr. De'ak to work of 1966 and 1968, by definition. I agree with Dr. De'ak's homily on current usage of tetracyclines. Of course his sentiments about unnecessary exposure apply to all medications, not simply to tetracyclines. I suspect Dr. De'ak has overlooked or misunderstood the implication of the following sentence: While the affected children did not receive any known immunosuppressive drug, they may have had an idiosyncratic sensitivity to the combined effect of varicella infection and ingestion of or exposure to some otherwise nonmalignant environmental factor.
DOWN WITH MOTHERHOOD?
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Aloe Vera and Vitamin E as Dermatologic Remedies
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Spotlight Issue on Signaling Networks in Cardiac Hypertrophy
Journal: Cardiovascular Research (2003)

A spotlight issue on Signaling Networks in Cardiac Hypertrophy is scheduled to appear in August, 2004.Considerable research efforts have been devoted to the understanding of the molecular mechanisms controlling cardiac hypertrophy.Traditionally, distinct signaling cascades have been dissected ''one-by-one''.However, a model where multiple pathways control hypertropy in parallel and independent of each other does not explain, for example, why inhibition of only one pathway usually suffices to suppress the hypertrophic response.It has emerged recently, in contrast, that the hypertrophic response is orchestrated by multiple, interdependent signaling cascades.These exciting new data suggest that any one specific signaling pathway activates and interacts with other hypertrophic signaling cascades.This new concept predicts that hypertrophy is controlled by cross-talking signaling networks rather than distinct, independent pathways.
Journal of Lipid Research, New York
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Inducing the Tryptophan Catabolic Pathway, Indoleamine 2,3-Dioxygenase (IDO), for Suppression of Graft-Versus-Host Disease (GVHD) Lethality.
Authors: Lisa Jasperson, Christoph Bucher, Angela Panoskaltsis-Mortari, Andrew Mellor, David H. Munn, Bruce R. Blazar
Journal: Blood (2009)
Error in Conflict of Interest Disclosure
Authors: Frank Schalkwijk, David Van Bodegom, Noel Mueller
Journal: JAMA Cardiology (2019)

John F. Heitner, MD; Raymond J. Kim, MD; Han W. Kim, MD; Igor Klem, MD; Dipan J. Shah, MD; Dany Debs, MD; Afshin Farzaneh-Far, MD, PhD; Venkateshwar Polsani, MD; Jiwon Kim, MD; Jonathan Weinsaft, MD; Chetan Shenoy, MD; Andrew Hughes, BS; Preston Cargile, BS; Jean Ho; Robert O. Bonow, MD; Elizabeth Jenista, PhD; Michele Parker, MS; Robert M. Judd, PhD
Minor myocardial injury after elective uncomplicated successful percutaneous transluminal coronary angioplasty with or without stenting: Detection by cardiac troponins Salam M. Saadeddin, Moh'd A. Habbab, Samia H. Sobki, Gordon A. Ferns. Riyadh Armed Forces Hospital and Prince Sultan Cardiac Center, Riyadh, Saudi Arabia, School of Biological Sciences, University of Surrey, Guildford, United Kingdom
Journal: Journal of the American College of Cardiology (2001)
Correction: ERCP using a conventional upper gastrointestinal endoscope for a patient with a type I duodenal stricture
Authors: Hirotsugu Maruyama, Yuki Kakiya-Ishikawa, Kojiro Tanoue, Kappei Hayashi, Masafumi Yamamura, Yasuaki Nagami, Yasuhiro Fujiwara
Journal: Endoscopy (2020)

Correction to:ERCP using a conventional upper gastrointestinal endoscope for a patient with a type I duodenal strictureEndoscopy 2020; 52(03): E110-E111DOI: 10.1055/a-1015-6547
Journal of Cell Biology, New York
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Use of nutritional supplements by family practice patients
Authors: E. C. English
Journal: JAMA (1981)

Sixty patients and their physicians were interviewed to assess their attitudes and practices with respect to nutritional supplements. Forty patients (67%) used nutritional supplements on a regular daily basis or had used them to treat an illness. Thirty-two (80%) of the supplement users believed supplements were effective in increasing energy, vitality, and physical strength. The majority of supplementation was suggested by friends, family, and lay publications. Thirty-seven (62%) of the supplement users had never discussed nutritional supplements with their physicians. For the most part, physicians were unaware of supplement use in their patients and did not regard this as their responsibility. Implications of the independent and unmonitored action of the patient in this aspect of health maintenance is discussed. (<i>JAMA</i>1981;246:2719-2721)
Abstract 694: Mathematical modeling of stromal fibroblast-mediated adaptive resistance to bortezomib in multiple myeloma
Authors: Elliot Eton, Kamran Kaveh, Sachin Khiste, Andrea Fernandes, Ashima Agarwal, Shiladitya Sengupta, Aaron Goldman
Journal: Cancer Research (2019)

Abstract Understanding intrinsic and adaptive resistance is crucial to overcoming multiple myeloma chemotherapy failure. We recently demonstrated that standard chemotherapy can induce cancer cells to phenotypically transition to a transient state of dormancy and drug tolerance. Further, targeting cells precisely during this transition can thwart the emergence of adaptive resistance (Goldman, 2015). However, it is not yet understood how the stromal contexture may contribute to this chemotherapy-induced drug tolerance. We developed a deterministic mathematical model containing a system of differential equations to examine how stromal fibroblasts temporally affect phenotypic switching between active and dormant, bortezomib-tolerant cancer cell states. The equations describe the total growth rate of each cell state population, which is influenced by that population’s count and baseline growth rate, the frequencies of transitions to and from the other cell state, the drug treatment concentration, and the population carrying capacity. The model also establishes that the presence of fibroblasts affects the frequency of transitions between the cell states. This framework is calibrated to in vitro data, and model simulations predict that bortezomib-tolerant myeloma cells may escape more quickly from dormancy and proliferate when they are incubated in the presence of fibroblasts than in their absence. This prediction is supported by preliminary experimental observations. The mathematical model could be adapted to predict how stromal fibroblasts, or the tumor microenvironment generally, may influence phenotypic switching in other cancers. Citation Format: Elliot Eton, Kamran Kaveh, Sachin Khiste, Andrea Fernandes, Ashima Agarwal, Shiladitya Sengupta, Aaron Goldman. Mathematical modeling of stromal fibroblast-mediated adaptive resistance to bortezomib in multiple myeloma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 694.
MODIFIED ENDOSCOPIC VACUUM THERAPY IN THE MANAGEMENT OF A DUODENAL TRANSMURAL DEFECT
Authors: DTH de Moura, ES do Monte Junior, KE Hathorn, AM da Ponte-Neto, IB Ribeiro, FS de Medeiros, M Coronel, CC Thompson, EGH de Moura
Journal: Endoscopy (2020)

Gastrointestinal transmural defects are difficult to manage and are associated with high rates of morbidity and mortality. A 64-year-old man with cholangiocarinoma status-post right hepatectomy presented on post-operative day 30 with sepsis and melena. EGD and CT scan showed a transmural duodenal wall defect associated with fluid collection. Endoscopic vacuum therapy(EVT) was considered. The patient was successfully treated with the modified EVT system, followed by 4 EVT system exchanges, and was discharged from the hospital 24-days after his initial procedure. This novel cost-effective modified EVT is feasible and appears to be as safe and effective as the traditional EVT system.